David M. Mintzer, MD

Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
View 1 additional location
Make an appointmentCall 800-789-7366
Headshot of David M. Mintzer, MD
Penn Medicine Provider

About me

  • Chief, Section of Hematology Oncology, Pennsylvania Hospital
  • Clinical Professor of Medicine (Hematology-Oncology)

My education and training

  • Medical School: Thomas Jefferson University
  • Residency: Pennsylvania Hospital
  • Fellowship: Thomas Jefferson University Hospital
  • Fellowship: Memorial Sloan-Kettering Cancer Center

Spoken languages

English
English

Reviews

Average Rating

2128 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
very attentive
Anonymous
May 2026
he is open to discussing various options and again he gives pros and cons to help you come to a decision on a path forward that is good for you while understanding the potential risks.
Anonymous
May 2026
very informative and professional
Anonymous
May 2026
dr mintzer is knowledgeable friendly and efficient

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Mintzer is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

David M. Mintzer But Where is My Doctor? The Increasing and Relentless Fragmentation of Oncology Care , Journal of Clinical Oncology , 41(26): 2023,4313

Mintzer D, Henry D FDA approvals in hematology and oncology, Part II: New oral formulations, RET and MET inhibitors, and CAR T-cell therapies , MDEdge: 2021

Mintzer D, Henry D FDA approvals in hematology and oncology: Novel agents and new tricks for old drugs , MDEdge: 2021

David Mintzer MKSAP 19, Oncology, Sections on lymphoma, melanoma, effects of cancer therapy and survivorship , American College of Physicians: 2021

Deye, DL; Mintzer D MKSAP 19 Audio companion , Oakstone: 2021

Mintzer D MKSAP 19, Oncology, Sections on lymphoma, melanoma, effects of cancer therapy and survivorship , American College of Physicians: 2021

Bryer E, Mintzer D, Henry DH 2019 At a Glance: Hem-Onc U.S. Drug Approvals , MDedge/Hematology and Oncology: 2019

Emily Bryer, Monique Neault, David Mintzer Managing Dying: Medical Care and Decision Making at the Very End-of-Life , Palliative Medicine & Care: Open Access: 2019,DOI: http://dx.doi.org/10.15226/2374-8362/6/1/00180

Bryer E, Mintzer D, Henry D 2018 At A Glance: Recently Approved Therapies in Oncology , MD Edge/Hematology and Oncology : 2019,://mdedge-files-live.s3.us-east-2.amazonaws.com

Deshields TL, Dueck AC, Rogers K, Brown JR, Shanafelt T, Mintzer D, Byrd JC Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). , Leukemia and Lymphoma : 2019,1-4